RxDoctor Payments Data

Andrea Boerger, NP

Family · Jamestown, NDNPI 1508489873

Payments from drug & device makers

$262in general payments, 2019–2025

Across 17 payments — averaging $15.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$43
  • Amgen$32
  • Teva Pharmaceuticals USA, Inc.$27
  • Boston Scientific$21
  • KCI USA, Inc.$17
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$16
  • plus $108 from 8 others

What the payments were for

  • Food & beverage$262100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$262 in reported general payments places this provider in the 60th percentile of 496 family providers in North Dakota.

See all family providers in North Dakota

Medicare billing

Part B allowed, 2024
$64,816
Medicare patients
341
Services billed
1,278

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide36$39,482
EliquisApixaban74$37,298
XareltoRivaroxaban33$12,851
Breztri AerosphereBudesonide/Glycopyr/Formoterol14$9,365
JanuviaSitagliptin Phosphate47$9,252
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr14$7,066
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate23$5,112
SymbicortBudesonide/Formoterol Fumarate14$4,830
Incruse ElliptaUmeclidinium Bromide12$4,538
Levothyroxine Sodium374$4,270
Omeprazole404$4,257
Atorvastatin Calcium395$3,947
Lantus SolostarInsulin Glargine,hum.Rec.Anlog36$3,825
Fluticasone-SalmeterolFluticasone Propion/Salmeterol16$3,366
Gabapentin374$3,360

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$14$39,48236 claims
Johnson & JohnsonXarelto$13$12,85133 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 496 family providers in North Dakota.

Other family in Jamestown

See the full list for North Dakota

Where these figures come from

Is this you, or does something look wrong? →